HT942526PCRPIDA_GG.pdf

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Program Announcement for the Defense Health Agency

Prostate Cancer Research Program

Idea Development Award

Funding Opportunity Number: HT942526PCRPIDA

Pre-Application Due: August 12, 2026

Application Due: September 2, 2026 https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

FY26 Prostate Cancer Idea Development Award 2

Content

Before You Begin 3

Basic Information Summarizes the funding opportunity, funding details, submission deadlines and review dates

Eligibility Details eligibility factors for the applicant organization and Principal Investigator

Program Description Describes the program mission and intent of the Idea Development Award; provides key award information and considerations; and outlines funding details

Application Contents Presents the two-step application process and instructions for preparing a pre-application and full application

Submission Requirements Provides locations for application packages, instructions for submitting pre-applications and full applications, and describes application verification

Application Review Information Outlines the processes for application compliance review, pre-application and full application selection/notification, and risk assessment. Also, details the review criteria for pre-application screening and both tiers of the CDMRP application review process – Peer Review and Programmatic Review

Federal Award Notices Outlines what a successful applicant can expect if recommended for funding

Post-Award Requirements References policy requirements for funded research; outlines reporting requirements and restrictions related to Principal Investigator changes and institutional award transfers

Other Information Outlines criteria for administrative actions including application rejection, modification, withdrawal and withhold

Appendix 1 Includes a checklist for all full application components to facilitate application submission

Appendix 2 Acronym List

FY26 Prostate Cancer Idea Development Award 3

Before You Begin

• Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission. User registration for each of these websites can take several weeks or longer.

Each applicant must ensure their registrations are active and up to date prior to application preparation.

• Read this funding opportunity announcement in the order it is written before beginning to prepare application materials. It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.

• To support application preparation, additional resources are available including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click to be taken to additional guidance and instructions within the General Application Instructions (GAI).

eBRAP Help Desk

301-682-5507 help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726 International: 1-606-545-5035 support@grants.gov

Questions regarding Grants.gov registration and Workspace.

https://sam.gov/ https://ebrap.org/eBRAP/public/index.htm https://grants.gov/register https://cdmrp.health.mil/#:~:text=Frequently%20Asked%20Questions%20%C2%BB https://cdmrp.health.mil/#:~:text=Guide%20for%20Intragovernmental%20%26%20Intramural%20Applicants https://ebrap.org/eBRAP/public/Program.htm#:~:text=Journey%20of%20an,Tier%20Review%20Process mailto:help@eBRAP.org mailto:support@grants.gov https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

Section Shortcuts Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 4

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission.

All applications must address one of the FY26 PCRP Overarching Challenges.

Distinctive Features:

• New Investigator Category: In addition to established investigators, the FY26 PCRP Idea Development Award encourages research ideas from investigators in the early stages of their careers (i.e., within 10 years after completion of their terminal degree). Qualified new investigators must identify a collaborator(s) experienced in prostate cancer research.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $13.6M to fund approximately 8 Idea Development Award – Established Investigator applications with total cost caps of $1.7M per award. The maximum period of performance is 3 years. The CDMRP expects to allot roughly $21M to fund approximately 10 Idea Development Award – New Investigator applications with total cost caps of $2.1M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

• Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern Time (ET), August 12, 2026

• Application Submission Deadline: 11:59 p.m. ET, September 2, 2026

• End of Application Verification Period: 5:00 p.m. ET, September 8, 2026

• Peer Review: November 2026

• Programmatic Review: March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PCRPIDA

Assistance Listing Number: 12.420

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 5

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status.

An investigator may be named as a PI on a single application to this program announcement. If an investigator is named multiple times as a PI, only the first application received will be accepted; additional applications will be administratively withdrawn. Although a PI may be eligible for both the New Investigator and Established Investigator categories, the PI may choose only one category; the choice of application category is at the PI’s discretion.

• New Investigator

By the application submission deadline date, the PI must:

○ Have an independent appointment (e.g., Assistant Professor, Research Scientist, or equivalent) with authority to supervise personnel and manage research funds, or demonstrate independence through: (1) serving as PI on peer-reviewed grants, (2) separate laboratory space or designated resources or (3) first or senior authorship on independent research publications.

○ Have not previously received a non-mentored PCRP Award (excluding the Exploration – Hypothesis Development Award).

○ Be an independent, early-career investigator within 10 years after completion of their terminal degree (excluding time spent in residency or on family medical leave but not spent as a postdoctoral fellow). The application may articulate any lapses in research time or appointments denoted in the biographical sketch.

○ Investigators working within a laboratory team are eligible if they can demonstrate independence through documentation such as: (1) appointment letter confirming independent research authority, (2) separate laboratory space or designated resources,

(3) independent grant submissions or funding or (4) first-author or senior-author publications on independent projects. Graduate students and junior postdoctoral fellows with less than three years of postdoctoral training by the application submission deadline are not eligible.

Investigators named as PI under the New Investigator category must confirm eligibility in Attachment 8, Eligibility Statement and independence, if applicable, in Attachment 9, Statement of Independence.

• Established Investigator

○ Independent investigators at all levels.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Content_Form_Full_App_Submission:~:text=pre%2Dapplication%20submission.-,Extramural%20Organization%3A,-A%20foreign%20or https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=Intramural%20DOW%20Organization%3A%20A%20subset%20of%20intragovernmental%20organizations%3B%20refers%20specifically%20to%20DOW%20organizations%2C%20including%20DOW%20laboratories%2C%20DOW%20military%20treatment%20facilities%2C%20and/or%20DOW%20activities%20embedded%20within%20a%20civilian%20medical%20center.

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 6

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible organizations, not to individuals. Refer to the GAI for additional recipient qualification requirements.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=APPENDIX%201-,RECIPIENT%20QUALIFICATION%20AND%20RESTRICTION%20INFORMATION,-A.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 7

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Prostate Cancer Research Program (PCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PCRP in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY25 totaled $2.445 billion. The FY26 appropriation is $75 million (M).

The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research.

3.1. Intent of the Idea Development Award

The FY26 PCRP Idea Development Award (IDA) intends to support new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission.

The PCRP encourages multidisciplinary and multi-institutional projects. Each proposed study must include a clearly stated plan for interactions among all team members and organizations involved. The plan must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.

3.1.1. Overarching Challenges for the IDA

All applications must address one of the following FY26 PCRP overarching challenges:

• Improve overall health, wellness and survivorship for those impacted by prostate cancer

Applications should aim to accelerate knowledge that translates to improve overall health and survivorship for those impacted by prostate cancer, with the goal of enhancing quality of life, overall health and survival. emotional health, healthy aging, cause-specific survival, cognitive function and other aspects of survivorship. Areas of particular interest include:

○ Biological basis of prostate cancer and its treatments on quality of life

○ The mental and emotional health of patients and their families/caregivers

○ Identification of groups of patients and their families at high risk of detriments in health and well-being

○ Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes and overall health and wellness

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 8

• Develop new treatments or improve upon existing therapies to improve outcomes for patients with lethal prostate cancer

Applications must be directly related to prostate cancer with a high risk of death, including high-risk localized disease, regional disease and/or metastatic prostate cancer.

Treatments may address any stage in the continuum of care, including local therapies such as surgery or radiation designed to treat patients with a high risk of death from the disease.

Proposed treatments are highly encouraged to consider preserving patient quality of life and not focus only on survival outcomes.

Applications should not focus on active surveillance or low-risk to intermediate-risk prostate cancer. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

• Enhance clinical care for all patients with prostate cancer

*Special emphasis on high-risk groups

Applications must be directly relevant to better understanding and/or reduction of factors that impact a person, their family or their caregiver’s ability to prevent, detect, manage and survive prostate cancer.

Factors may include physical, mental or emotional health differences experienced primarily in populations at high risk for prostate cancer, including Service Members and Veterans.

• Define the biology of prostate cancer progression to lethal prostate cancer to reduce death

Applications must be directly related to high-risk, very high-risk and metastatic prostate cancer. The FY26 PCRP also strongly encourages research involving patient-derived materials or specimens related to ongoing or completed clinical trials.

Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

3.1.2. Key Elements for the IDA

• Innovation: Research deemed innovative may represent a new paradigm, challenge current paradigms, look at existing problems from new perspectives, leverage unique study populations, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not innovative. The PCRP encourages projects involving multidisciplinary and/or data science approaches.

• Impact: Applications must address and provide a solution to one or more of the FY26 PCRP Overarching Challenges. The application should clearly describe the potential impact of the research, both short-term and long-term, in addressing the FY26 PCRP overarching challenge(s). High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

• Preliminary Data: Due to this award’s emphasis on innovation, the PCRP encourages, but does not require, presentation of preliminary data relevant to prostate cancer and the proposed project. Any unpublished preliminary data provided should originate from the laboratory of the PI or member(s) of the research team. Regardless of whether the https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 9 application includes preliminary data, applications should present a sound scientific rationale established through logical reasoning and/or critical review and analysis of the literature.

New Investigator Category: The FY26 PCRP Idea Development Award mechanism encourages research ideas from investigators in the early stages of their careers. The New Investigator category allows applicant organizations to name PIs early in their faculty appointments or in the process of developing independent research careers. Applications submitted to the New Investigator category are subject to different peer review criteria for personnel and must include a collaborator (or collaborators) who has (have) experience in prostate cancer research, as demonstrated by a record of funding and publications. For New Investigator applications, at least one collaborator with demonstrated experience in prostate cancer research (as evidenced by funding and publications) must be included. The application must describe how the collaboration(s) will augment the PI's expertise to better address the research question. A letter of collaboration from each named collaborator is required, describing the collaborator's role and specific contributions to the proposed work. All PIs named under the New Investigator category must meet specific eligibility criteria.

3.1.3. Other Important Considerations for the IDA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical trials are not allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

The following encouragement is broadly applicable across many CDMRP programs, including the PCRP, A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PCRP priorities.

3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be grants

(31 USC 6304).

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in https://arriveguidelines.org/arrive-guidelines https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 10

3.3. Funding Details

Established Investigator

Period of Performance: The maximum period of performance is 3 years.

Cost Cap: The application’s total costs budgeted for the entire period of performance should not exceed $1.7M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

New Investigator

Period of Performance: The maximum period of performance is 4 years.

Cost Cap: The application’s total costs budgeted for the entire period of performance should not exceed $2.1M. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 4 years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

An award’s maximum period of performance and maximum direct costs depend on the eligibility of the PI, as defined in Section 2.1.2, Principal Investigator.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

• Travel in support of multi-institutional collaborations.

• Costs for one investigator to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PCRP Idea Development Award.

Must not be requested for:

• Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

• Clinical trial costs.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=Period%20of%20Performance%3A%20The%20time%20interval%20between%20the%20start%20of%20a%20federal%20award%20and%20the%20planned%20end%20date.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=in%20project%20activities.-,Cost%20Cap%3A,-The%20maximum%20cost https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=Period%20of%20Performance%3A%20The%20time%20interval%20between%20the%20start%20of%20a%20federal%20award%20and%20the%20planned%20end%20date.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=in%20project%20activities.-,Cost%20Cap%3A,-The%20maximum%20cost

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 11

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a full application submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

LOI (one-page limit): Provide a brief description of the research to be conducted. Include the FY26 PCRP Overarching Challenge the research will address.

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):

IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

○ Attachment 1: Project Narrative (15-page limit): Upload as “ProjectNarrative.pdf”.

Describe the proposed project in detail using the outline below.

– Background: Present the ideas and reasoning behind the proposed research and the FY26 PCRP Overarching Challenge(s) that will be addressed. The application must demonstrate logical reasoning and provide a sound scientific rationale for the proposed project as established through a critical review and analysis of published literature; include relevant literature citations. Describe previous experience most pertinent to this application. While not required, include any preliminary data to support the scientific rationale.

– Hypothesis or Objective: State the hypothesis to be tested or the objective to be reached.

– Specific Aims: Concisely explain the project’s specific aims. If this application is part of a larger study, present only tasks that this award would fund.

https://ebrap.org/eBRAP/public/index.htm https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=APPENDIX%202.%0AFORMATTING%20GUIDELINES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=(a)%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20SF424%20(R%26R)%20%E2%80%93%20Application%20for%20Federal%20Assistance%20Form https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Project%20Narrative%3A,-Attach%20as%20%E2%80%9CProjectNarrative https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_Grants:~:text=IV.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20GRANTS.GOV https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_eBRAP:~:text=V.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20eBRAP

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 12

– Research Strategy and Feasibility:

▪ Describe the experimental design, methods and analyses, including appropriate controls, in sufficient detail for scientific evaluation that will include an assessment of overall project feasibility.

▪ Address potential problem areas and present alternative methods and approaches.

▪ Clearly describe the statistical plan and the rationale for the statistical methodology as well as an appropriate power analysis, including the statistical expertise available to support the analysis, if applicable. If animal studies are proposed, describe how they will be conducted in accordance with the ARRIVE guidelines 2.0 (Animal Research Reporting In Vivo Experiments) to achieve reproducible and rigorous results.

▪ Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

▪ If human subjects or human biological samples will be used, provide evidence supporting the availability of and access to any populations/samples required for the study, including any clinical expertise. Include a detailed plan for the recruitment of subjects or the acquisition of samples, and for acquiring any additional research resources necessary for conducting the proposed research project. This award cannot support clinical trials. For clinical research, see Attachment 10 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.

▪ Clearly identify the source of any proposed cell lines and whether they were recently authenticated and/or tested for mycoplasma contamination, if applicable.

▪ Describe how the clinical relevance of the anticipated findings will be determined and whether the results will be validated in the appropriate patient cohorts, if applicable.

– Required Collaborator (for New Investigator category only): Name the required collaborator(s); describe their prostate cancer-related expertise and how the contribution of the collaborator(s) will support the PI and project.

If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, Appendix 4, for additional considerations.

○ Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

https://arriveguidelines.org/arrive-guidelines https://arriveguidelines.org/arrive-guidelines https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Use_Of_DOW_Dept_Veterans_Affairs_Resource:~:text=APPENDIX%204.%0AUSE%20OF%20DOW%20OR%20U.S.%20DEPARTMENT%20OF%20VETERANS%20AFFAIRS%20RESOURCES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Supporting%20Documentation%3A,-Combine%20and%20attach

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 13

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support: Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI’s Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

▪ New Investigators (if applicable): The PCRP strongly encourages applications for the New Investigator category to provide a signed letter from each collaborating individual or organization that describes how they will support the project, including unique expertise and/or availability of and access to research resources.

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Intellectual Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 14

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP’s expectations for making data and research resources publicly available.

○ Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the scientific rationale behind the proposed research project.

Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached.

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls.

Military Relevance: Describe how the study is relevant to military health.

Impact: Summarize how the proposed research will address and provide a solution to one or more of the FY26 PCRP Overarching Challenges and ultimately provide progress toward eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers experiencing the impact of the disease.

○ Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.

The lay abstract should address the points outlined below in a manner that is readily understood by readers without a background in science or medicine. Avoid overuse of scientific jargon, acronyms and abbreviations. Do not duplicate the technical abstract.

– Summarize the objectives and rationale for the proposed research.

What are the likely contributions of this study to the FY26 PCRP Overarching Challenges?

– What population will the research help, and how will it help them?

– What are the potential applications, benefits and risks of the anticipated outcomes?

– What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?

– What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?

○ Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.

Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

https://ebrap.org/eBRAP/public/Program.htm#:~:text=Directive%20on%20Sharing%20Data%20and%20Research%20Resources https://ebrap.org/eBRAP/public/Program.htm#:~:text=Suggested%20SOW%20Format https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Lay%20Abstract%3A,-Attach%20as%20%E2%80%9CLayAbs https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Technical%20Abstract%3A,-Attach%20as%20%E2%80%9CTechAbs https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Statement%20of%20Work%3A,-Attach%20as%20%E2%80%9CSOW

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 15

○ Attachment 6: Impact Statement (one-page limit): Upload as “Impact.pdf”. Explain in detail why the proposed research project is important, as follows:

– Describe the short-term impact: Detail the anticipated outcome(s)/product(s) that will be directly attributed to the results of the proposed research, including any clinically relevant results. Summarize how the anticipated outcome(s)/product(s) will provide a foundation for future research projects that will enable progress towards a solution to one or more of the FY26 PCRP Overarching Challenges.

– Describe the long-term impact: Explain the anticipated long-term gains from the proposed research, including the anticipated advantages that the new understanding may contribute to the goal of elimination of death and suffering from prostate cancer.

– Relevance to military health: Briefly describe how the proposed research is relevant to Service Members, Veterans and/or their Families.

○ Attachment 7: Innovation Statement (one-page limit): Upload as “Innovation.pdf”.

Describe how the proposed work is innovative by proposing new paradigms, challenging existing paradigms or otherwise being highly creative. Describe how the proposed research represents more than an incremental advancement on published data.

Consult the following examples for ways in which the proposed work may be innovative:

– Study Concept: Investigation of a novel idea and/or research question.

– Research Methods or Technologies: Use of novel research methods; new technologies, including technology development; or unique study populations to address a research question.

– Existing Methods or Technologies: Application or adaptation of existing methods or technologies for novel research or clinical purposes.

○ Attachment 8: Eligibility Statement (one-page limit): Upload as “Eligibility.pdf” (Attachment 8 is only applicable and required for applications submitted under the New Investigator category). The Eligibility Statement will only be used for administrative purposes to confirm eligibility and will not be forwarded for peer or programmatic review. Provide a statement, signed by the PI and Department Chair, Dean, or equivalent official verifying that the PI will have met the eligibility requirements by the application submission deadline. The statement should clearly state that the PI:

– Has the freedom to pursue independent research goals without formal mentorship;

– Has not previously received a non-mentored PCRP Award (excluding the Exploration Hypothesis-Development Award); and

– Is an independent, early-career investigator within 10 years after completion of their terminal degree by the time of the application submission deadline (excluding time on family medical leave except if that family leave occurred during postdoctoral training). Provide an explanation for any lapses in research time or appointments.

○ Attachment 9: Statement of Independence (one-page limit): Upload as “Independence.pdf” (required only for investigators not yet in an independent faculty position). For investigators not yet in an independent faculty position, provide a statement, signed by the PI and the PI’s mentor, that supports the PI’s ability to perform as an independent researcher. The Statement of Independence must include the following components:

– PI’s name, organization and application title

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 16

– Beginning and ending dates (month/year) of postdoctoral training

– Date (month/year) the PI began or will begin independent research in the proposed setting

– Other information that attests to the PI’s independence (e.g., grants/fellowships obtained; awards/appointments earned by the PI)

○ Attachment 10: Inclusion of Women and Minorities (four-page limit): Upload as “Inclusion.pdf”. (Attachment 10 is only applicable and required for applications that propose clinical research.) Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. The “Public Health Service (PHS) Inclusion Enrollment Report” is a three-page fillable PDF form, that can be downloaded from eBRAP.

○ Attachment 11: Transition Plan (one-page limit): Upload as “Transition.pdf”.

Provide information on potential methods and strategies to move the project’s findings to the next phase of development, clinical trials, and/or delivery to the commercial market after successful completion of the award (e.g., specific potential industry partners, specific funding opportunities to apply for). Provide a realistic timeline for near-term clinical investigation. In addition, provide a plan to distribute the findings or intervention to the prostate cancer community.

○ Attachment 12: Representations (Grants.gov submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations document available on eBRAP.

○ Attachment 13: Suggested Intragovernmental/Intramural Budget Form (if applicable): Upload as “IGBudget.pdf”. If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the https://ebrap.org/eBRAP/public/Program.htm#:~:text=Statement%20of%20Work-,Public%20Health%20Service%20Inclusion%20Enrollment%20Report,-n/a https://ebrap.org/eBRAP/public/Program.htm#:~:text=Required%20Representations https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=Intramural%20DOW%20Organization%3A%20A%20subset%20of%20intragovernmental%20organizations%3B%20refers%20specifically%20to%20DOW%20organizations%2C%20including%20DOW%20laboratories%2C%20DOW%20military%20treatment%20facilities%2C%20and/or%20DOW%20activities%20embedded%20within%20a%20civilian%20medical%20center.

https://ebrap.org/eBRAP/public/Program.htm#:~:text=Suggested%20Intragovernmental/Intramural%20Budget https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=B.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20Representations https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=Suggested%20Intragovernmental/Intramural%20Budget%20Form%2C%20if%20applicable%3A

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 17

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

i. Research & Related Senior/Key Person Profile (Expanded)

○ Biographical Sketch

○ Current/Pending Support

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) (if applicable, Grants.gov submissions only)

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

External Link to the GAI

Grants.gov

External Link to the GAI eBRAP.org https://www.esd.whs.mil/Portals/54/Documents/DD/issuances/dodi/320012p.pdf?ver=2018-12-17-130508-423 https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_IV:~:text=C.-,Additional%20Application%20Materials,-The%20following%20are https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_V:~:text=B.-,Additional%20Application%20Materials,-The%20following%20are https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_V:~:text=E.-,DOW%20Data%20Management%20Plan,-If%20recommended%20for

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Idea Development Award 18

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PCRPIDA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has…